Skip to search formSkip to main contentSkip to account menu

7-hydroxystaurosporine

Known as: 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino), 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one, 2,3,9,10,11,12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-, 7-hydroxy-staurosporine 
A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine… 
National Institutes of Health

Related topics

Related topics

17 relations

Broader (3)

Antineoplastic AgentsProtein Kinase InhibitorsStaurosporine
CHEK1 protein, humanCyclin-Dependent KinasesNCIt Antineoplastic Agent TerminologyNegative Regulation of G1 to S Transition

Narrower (2)

UCN 01UCN 02

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors
Purpose: Based on preclinical data showing synergy between 7-hydroxystaurosporine (UCN-01) and platinum agents, a phase I trial… 
Highly Cited
2007
Highly Cited
2007
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Interactions between UCN-01 and HMG-CoA reductase inhibitors (ie, statins) have been examined in human leukemia and myeloma cells… 
Highly Cited
2005
Highly Cited
2005
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
PURPOSE Preclinical studies indicate that the cyclin-dependent kinase and protein kinase C inhibitor 7-hydroxystaurosporine (UCN… 
Highly Cited
2004
Highly Cited
2004
7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation
7-Hydroxystaurosporine (UCN-01) infused for 72 hours by continuous i.v. infusion induced insulin resistance during phase I… 
Highly Cited
2002
Highly Cited
2002
Abrogation of the S Phase DNA Damage Checkpoint Results in S Phase Progression or Premature Mitosis Depending on the Concentration of 7-Hydroxystaurosporine and the Kinetics of Cdc25C Activation*
DNA damage causes cell cycle arrest in G1, S, or G2 to prevent replication on damaged DNA or to prevent aberrant mitosis. The G1… 
Highly Cited
2002
Highly Cited
2002
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Altered and deregulated cyclin-dependent kinase (cdk) activity is now believed to play a major role in the pathogenesis of head… 
Highly Cited
2001
Highly Cited
2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
PURPOSE To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01… 
2000
2000
Protein Kinase C ζ Isoform is Critical for Proliferation in Human Glioblastoma Cell Lines
Previous studies have confirmed that proliferation in glioblastoma cell lines can be blocked by non-isoform specific protein… 
2000
2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Emerging evidence suggests that apoptosis is an important mechanism of tumor cell death from antineoplastic therapy. 7… 
1993
1993
Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo.
The effects of a newly synthesized compound, N-ethoxycarbonyl-7-oxo-staurosporine (NA-382), on multidrug resistance in tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)